Invectys announces FDA approval to launch a Phase II clinical trial of its therapeutic cancer vaccine INVAC-1 After a recent capital raise of 4.3 M€s another…
After its Phase I success, Invectys raises €4.3 million to enter Phase II with both of its anti-cancer vaccines Paris, July 12th, 2017 – This round brings…
Presentation of the Invectys clinical trial results on cancer patients at the most important worldwide oncology meeting taking place this year in Chicago, USA Paris,…
Invectys at the Third International Symposium on Immunotherapy organised by The Institute for Cancer Vaccines & Immunotherapy (previously known as the Cancer…
Invectys attend ASCO 2017 meeting in Chicago Invectys will be at the Annual Meeting is organized by American Society Of Clinical Oncology (ASCO). This meeting…
Invectys will attend the Sachs Forum in Zürich, 6. March – 7. March 2017 Meet Invectys there ! More information: invest@invectys.com The 10th…
J.P. Morgan 35Th Annual Healthcare Conference 2017 San-Francisco…
Medicen Paris Region et Invectys annoncent le succès du projet TelVac pour la recherche d’un candidat vaccin contre le cancer…
